Responsiveness of lymphocytes to soluble extracts of prostatic tumors and abrogation by serum-blocking factor(s).
Preliminary evidence is presented suggestive of antitumor immunity, cross reactive with allogeneic extracts from tumors of the same type, and serum-blocking factor(s), which appear to be specific to autologous tumor only, in patients with prostatic cancer employing the method of leukocyte adherence inhibition.